Addendum
Abemaciclib (breast cancer; combination with fulvestrant) - Addendum to Commission A18-73
Report documents
-
Addendum
Abemaciclib (breast cancer; combination with fulvestrant) - Addendum to Commission A18-73
Dossier assessment
Indication:
Women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Result of dossier assessment:
Conclusion of dossier assessment A18-73 unchanged
Additional information
Federal Joint Committee (G-BA)
2019-05-02 A G-BA decision was published.
Project details
- Project no.
- A19-25
- Commission
- Commission awarded on 11.03.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib (breast cancer; adjuvant treatment) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed